US Food and Drug Administration

FDA calls for label change on anti-diarrhoea drug to stem misuse by opioid users

The US Food and Drug Administration (FDA) has called for sponsors of over-the-counter (OTC) anti-diarrhoea drug, loperamide, to change the way they label and package the drug to stem concerning misuse of the drug.

In a  FDA commissioner Scott Gottlieb said loperamide misuse had been increasing in the United States with users attempting to achieve the euphoric effects of opioids and seeing it as a potential alternative to manage opioid withdrawal symptoms.

The maximum approved daily dose of loperamide, which is also sold as Imodium, for adults is 8mg per day for OTC use and 16mg per day for prescription use.

“Loperamide is safe at these approved doses. But when higher than recommended doses are taken we’ve received reports of serious heart problems and deaths with loperamide, particularly among people who are intentionally misusing or abusing high doses,” said Gottlieb.

The commissioner said the abuse of loperamide required the purchase of “extremely large quantities”, often achieved through buying large bottles of loperamide — a common form of packaging for the drug in pill form.

Therefore, the FDA is requesting that packages contain a limited amount of loperamide appropriate for use for short-term diarrhoea according to the product label.

Gottlieb said the FDA also plans to those who distribute loperamide online, through retail websites, to ask them to take voluntary steps to help address this abuse issue.

“I believe anyone who is distributing healthcare products has an obligation to be a partner in helping address the most pressing public health challenges such as opioid abuse,” he added.

In October 2017, the Medicines Healthcare products Regulatory Agency (MHRA) of serious cardiac adverse reactions in patients misusing or abusing loperamide by taking high or very high doses of the drug. It said that pharmacists should remind patients not to take more than the recommended dose on the label, and should report all suspected adverse reactions, including those associated with abuse or misuse, to the Yellow Card Scheme.

Citation: The Salvadore DOI: 10.1211/PJ.2018.20204338

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00
  • Physicochemical Principles of Pharmacy

    This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.

    £48.00
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00
  • FASTtrack: Pharmacology

    FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.

    £25.00
  • Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete

Supplementary images

  • Imodium-loperamide-blister-pack-short-term-use

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

steroid-pharm.com

steroid-pharm.com

www.steroid-pharm.com/boldenone.html